Clinical Trials Logo

Clinical Trial Summary

This study will provide feasibility data regarding the conduct of a clinical trail evaluating the use of early aggressive inpatient intravenous rehydration in children with Shiga Toxin producing E. coli infection.


Clinical Trial Description

Background: Shiga toxin-producing Escherichia coli (STEC) cause a spectrum of disease, ranging from asymptomatic carriage to bloody diarrhea and the hemolytic uremic syndrome (HUS). HUS is caused by a toxin that destroys red blood cells, consumes platelets and impairs kidney function. HUS results in morbidity and even death in otherwise healthy children. Over the last 30 years however, there has been extremely limited progress in preventing acute and long-term complications in children with STEC infection. However, it is believed that Shiga toxins generate clots or blockages in the kidneys that damage it much the way strokes cause brain damage. There is emerging evidence that if children with STEC infection are recognized early, then the interval between diarrhea onset and the presence of HUS could be exploited to preserve kidney function through the use of intravenous rehydration. Study Design: The investigators propose to conduct the first randomized clinical trial of volume expansion therapy in children with STEC infection. Employing Alberta's unique province-wide microbiology network and its only two pediatric tertiary care centres, the investigators will conduct a proof of principal feasibility study that evaluates novel technologies to identify STEC infected children and those at risk for HUS. Objectives: The primary outcome will be process: number of children recruited. Secondary outcomes will include: 1) resources: retention; refusal; compliance; eligibility criteria; questionnaires; data collection tools; and time requirements; 2) management: capacity and impact on clinical services; 3) scientific: utility of point-of-care STEC diagnostics; use of urine biomarkers to identify high risk children, monitoring of kidney injury and response to therapy; and safety. Significance: This pilot will provide the necessary data to integrate novel technologies into the design and conduct of a multicentre, multinational, clinical trial that will reduce morbidity and mortality from STEC infection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03275792
Study type Interventional
Source University of Calgary
Contact
Status Withdrawn
Phase Phase 1
Start date May 2020
Completion date April 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05219110 - Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection Phase 3
Completed NCT05569746 - A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS Phase 2
Recruiting NCT05985122 - New Analytic Tools for aHUS and C3G Diagnosis N/A
Not yet recruiting NCT06389474 - Efficacy of INM004 in Children With STEC-HUS Phase 3
Completed NCT01406288 - Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 N/A
Terminated NCT04132375 - Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS Phase 2/Phase 3
Completed NCT03776851 - Erythropoietin in Hemolytic Uremic Syndrome Phase 4
Completed NCT01666548 - Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects N/A
Recruiting NCT04745195 - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Active, not recruiting NCT03580941 - Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy